Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
Bruce R Conklin, MD Joins the CMTA STAR Advisory Board
…Advisory Board (SAB). The SAB is comprised of world-leading experts who provide scientific input and evaluation of ongoing or proposed CMTA funded research projects and guide the CMTA’s research strategy….
Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy
…Research Today Not yet registered with Patients as Partners in Research? Click the button below to register today! Registering ensures you are the first in line for any CMT research…
CMTA-STAR Alliance Partner NMD Pharma Announces FDA Orphan Drug Designation for NMD670
…Partners in Research Today CMTA invites you to advance CMT research by filling out a Patients as Partners in Research profile. Not yet registered? Click the button below to join…
Inherited Neuropathies Consortium Study 6603: Development of CMTPedS Scale for Children with CMT
The Charcot-Marie-Tooth Association (CMTA), through its strategic alliance with the Inherited Neuropathy Consortium (INC), is proud to share this important opportunity for families living with Charcot-Marie-Tooth disease (CMT). This longitudinal…
CMTA-STAR Alliance Partner NMD Pharma Publishes Transformative Study on Charcot-Marie-Tooth Disease
…with CMT. Registering lets you stay informed about the latest research opportunities, including the SYNAPSE-CMT trial, and other CMT research participation opportunities. Together, we accelerate the research that brings us…
Gene Therapy for CMT1A, 1B, and X1: Progress in Nanoparticles
…in Research Today Not yet registered with Patients as Partners in Research? Click the button below to register today! Registering ensures you are the first in line for any CMT…
Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT
The Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research (STAR) initiative, is proud to support groundbreaking research that seeks to deepen our understanding of CMT2A and CMT2F, two axonal…
Exploring New Therapeutic Pathways for CMT1B: UPR Activation
Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Milan, Italy, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR), have made encouraging progress in…
Who Inspires You to Give?
…research service companies that are pursuing therapy development. STAR Research Agenda for Demyelinating Forms of CMT Download PDF STAR Research Agenda for Axonal Forms of CMT Download PDF “Hope is…
2021_Spring_CMTA_Report
…Accelerate Research (STAR) project launched Strategy To Accelerate ResearchStrategy To Accelerate Research 2019 Stem cell studies published, first gene modifier and skin biopsy assay (treatment-responsive for CMT1A); CMT Health Index…